A Phase 1B, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Inhalation Solution Given Daily for 14 Days to Stable Pediatric Cystic Fibrosis Patients.

Trial Profile

A Phase 1B, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Inhalation Solution Given Daily for 14 Days to Stable Pediatric Cystic Fibrosis Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2015

At a glance

  • Drugs Levofloxacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections
  • Focus Adverse reactions
  • Sponsors Mpex Pharmaceuticals
  • Most Recent Events

    • 03 Apr 2012 New source identified and integrated (Oregon Health and Science University Institutional Review Board: IRB00007733).
    • 14 Nov 2011 New source identified and integrated (Oregon Health and Science University Institutional Review Board; IRB00007733).
    • 04 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top